Background: Deramiocel, a heart-derived cellular therapy, improved cardiac and skeletal muscle function in phase 1-2 studies of Duchenne muscular dystrophy (DMD). This phase 3 study was conducted to confirm the efficacy and safety of deramiocel in advanced DMD.Methods: HOPE (Halt cardiOmyopathy ProgrEssion)-3, a multicenter, randomised (1:1 ratio), double-blind placebo-controlled study, included 106 participants with DMD aged ≥10 years. Investigational product was infused intravenously every 3 months in outpatient settings. Skeletal and cardiac muscle function, measured by the total and mid-level Performance of the Upper Limb 2.0 (PUL2.0), and cardiac magnetic resonance (CMR) imaging outcomes, including left ventricular ejection fraction (LVEF) and late gadolinium enhancement (LGE), were evaluated at 12 months. A global statistical test (GST) combined total PUL2.0, CMR LVEF, and patient global impression of severity.Findings: The primary and all Type-1-error controlled secondary efficacy endpoints demonstrated significant improvements in the deramiocel group versus placebo. For PUL2.0, mean percent change at 12 months favoured deramiocel by 4.55% for Total (95% CI 0.47 - 8.63; p=0.029) and 8.12% for Mid-level (95% CI 2.12 - 14.11; p=0.008). For LVEF, ranked change from baseline favoured deramiocel by 11.65 (95% CI 0.47 - 22.82; p=0.041). The absolute mean change in LVEF(%) showed a treatment benefit of 2.4-percentage points. For LGE, a measure of cardiac scarring, the mean change from baseline in number of affected segments favoured deramiocel by -3.00 (95% CI -5.50 - 0.51; p=0.022). The GST favoured deramiocel with z-score of 0.27 (95% CI 0.05 - 0.49; p=0.015). Deramiocel had a safety profile comparable to that of placebo.Interpretation: Deramiocel safely slows disease progression in advanced DMD, preserving both skeletal and cardiac muscle function. Administered quarterly in a simple outpatient regimen, deramiocel is a promising treatment for skeletal and cardiac disease in DMD, agnostic to the precise underlying genetic lesion.